AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01710189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TicoVac
Description: Intramuscular immunisation to right deltoid muscle (Group 1) or right upper anterolateral thigh muscle (Group 2).
Study NCT00674466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.5 mg or 2.0 mg CJC-1134-PC
Description: twice-a-week
Study NCT00674466 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice-a-week
Study NCT03167684 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oral appliance therapy
Description: Fitted oral appliance
Study NCT03976466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Antibiotic local prophylaxis with medicated calcium sulfate beads
Description: Antibiotic prophylaxis in patients with non-modifiable risk factors for periprosthetic joint infection
Study NCT03976466 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Classical parenteral antibiotic prophylaxis
Description: Antibiotic prophylaxis in patients with non-modifiable risk factors for periprosthetic joint infection
Study NCT01557322 — intervention group
Intervention type: BIOLOGICAL
Intervention: etanercept
Description: This is a Non-interventional study. The data is being analyzed retrospectively. The data consists of 2 cohorts; biologic and non-biologic
Study NCT01557322 — intervention group
Intervention type: DRUG
Intervention: methotrexate (MTX)
Description: This is a Non-interventional study. The data is being analyzed retrospectively. The data consists of 2 cohorts; biologic and non-biologic
Study NCT02716337 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Addition of human milk fortifiers according to human milk analysis
Study NCT04199260 — intervention group
Intervention type: DEVICE
Intervention: papilocare vaginal gel
Description: Papilocare is a gel vaginally administered by a single-dose cannula. Vaginal gel formulation is effective as a local treatment with controlled systemic absorption and rapid and efficient distribution
Study NCT01265901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: As per label.
Study NCT01265901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: As per label.
Study NCT01265901 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Intradermal injection of GM-CSF as adjuvant.
Study NCT01265901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: One single low-dose i.v. infusion prior to the first vaccination
Study NCT01265901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMA901
Description: Intradermal vaccinations with IMA901 vaccine.
Study NCT01599923 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antivenin Centruroides (scorpion) equine immune F(ab')2
Description: 3 vials of Alacramyn reconstituted in 50 ml of normal saline as an IV infusion over 10 minutes.
Study NCT03042598 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biphasic Cuirass Ventilation
Description: The RTX Respirator will be applied to the patient's chest to provide non-invasive ventilatory support using a Biphasic Cuirass Ventilation technology to increase the safe apnic period during intubation.
Study NCT02201056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-935
Description: TAK-935 oral solution
Study NCT02201056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-935 placebo-matching oral solution
Study NCT01931735 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Randomized Meniscectomy
Description: Arthroscopic meniscectomy
Study NCT01931735 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Randomized Lavage
Description: Arthroscopic Lavage
Study NCT01931735 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard of Care Meniscectomy Pre-Amend
Description: Arthroscopic meniscectomy
Study NCT01931735 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard of Care Meniscectomy Post-Amend
Description: Arthroscopic meniscectomy
Study NCT03515382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1690
Description: A single oral dose of GLPG1690.
Study NCT03515382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: A single oral dose of itraconazole.
Study NCT03515382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: A single oral dose of voriconazole.
Study NCT01970787 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation (RFA) using the HALO Ablation System
Study NCT01395823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: ergocalciferol supplementation
Description: 50,000 IU given either weekly; weekly for 3 months then monthly for 3 months; monthly
Study NCT01395823 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo pill given weekly, weekly for 3 months then monthly for 3 months; monthly
Study NCT03033459 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Motivational Interviewing (MI) is a psychosocial intervention designed to help individuals increase readiness for behavior change by increasing intrinsic motivation and resolving ambivalence. MI founders MI conversations help clients change behavior through identifying and resolving discrepancies between goal behaviors and actual behaviors. Behavior change is promoted through the elicitation of change talk, or client-verbalized arguments for change. In MI, change talk is elicited through two major components: the therapeutic relationship, or the embodiment of the spirit of MI, and technical skill.
Study NCT03033459 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation Control
Description: Psychoeducation on infant development, age 0-15 months, brief education on breastfeeding.
Study NCT05211271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment of cervical neoplasia by thermal ablation
Description: Women screened for cervical cancer by visual inspection with diluted acetic acid (VIA) presenting lesions eligible for ablative treatment were treated by thermal ablation. The treatment consisted in applying the probe on the lesion for 45 seconds at 100 degrees Celsius, with one to up to five applications depending on the lesion size. Following treatment, women were inquired about the pain level during the procedure, their satisfaction level of the procedure and whether they would recommend this treatment to their relatives. Women had a follow-up visit at 6 weeks to assess any complication of the procedure. Women were rescreened at 12 months, to evaluate the cure rate and any long-term adverse events.
Study NCT02725125 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EPCAM-targeted CAR-T cells
Description: This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-EPCAM-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
Study NCT01677143 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine 5mg/ml
Description: 5 ml in trocar area
Study NCT01677143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 5mg/ml
Description: 5 ml in trocar area
Study NCT03951974 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Emotion Regulation Strategy Development
Description: Participants will work one-on-one with an interventionist to develop goals (in the form of implementation intentions) to develop social emotion regulation strategies to combat frequent emotional challenges.
Study NCT03951974 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: Participants will work one-on-one with an interventionist to report on their frequent emotional challenges, and report the emotion regulation strategies that they frequently use to combat them.
Study NCT03522714 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fluid Immersion Simulation System
Description: Dolphin Fluid Immersion Simulation® System Mattress will be used
Study NCT03522714 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air Fluidized Bed System
Description: Air Fluidized Bed (Clinitron) will be used.
Study NCT00779974 — intervention group
Intervention type: OTHER
Intervention: Evaluation
Description: For this research study each enrolled subject will have a clinical exam, including range of motion (ROM), and strength testing. The lift off and belly compression tests will be performed. An ultrasound of the shoulder will be done to determine the integrity of the subscapularis tendon. An EMG will be done to determine functionality of the subscapularis.
Study NCT00953537 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: capecitabine
Study NCT00953537 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: laboratory biomarker analysis
Study NCT00953537 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: pharmacological study
Study NCT04520802 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 18F-DPA-714 PET/CT neuroimaging
Description: * Pre- and postoperative neuroimaging using 18F-DPA-714 PET/CT and brain MRI.~* Longitudinal neuropsychological examinations (up to 6 months postoperatively)~* Blood samples are drawn to assess the severity of the systemic inflammatory response
Study NCT02404389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Treatment
Description: Topical application for two treatment cycles with twice daily applications, separated by a 4 week treatment pause and followed by 8 week treatment free follow-up.
Study NCT03255915 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A placebo pod-IVR containing microcrystalline cellulose pods.
Study NCT03195127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multimodal physical therapy
Description: Consist of limb strengthening exercises, endurance training, and balance/coordination drills. These exercises and training maneuvers may involve the use of handheld weights, nautilus weight equipment, elastic exercise bands, stationary exercise machines (recumbent exercise cycles, hand ergometer cycles), or treadmills. If the subject is fit enough, Tai Chi may be added to as a training method to help improve your balance and strength. In addition, the subject will be asked to wear an accelerometer on their wrist
Study NCT03334747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAE609
Description: Exploration of different doses of KAE609 to establish safety profile.
Study NCT02404389 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Investigational Treatment
Description: Topical application for two treatment cycles with twice daily applications, separated by a 4 week treatment pause and followed by 8 week treatment free follow-up.
Study NCT02404389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Description: Topical treatment with Aldara 3 times per week. The group will be open-label, but however blinded to the efficacy assessor, and followed by 8 week treatment free follow-up.
Study NCT02947438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPREX®
Description: Recombinant human erythropoietin falls under the pharmacological class of haematopoietic / anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000.
Study NCT02947438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPIAO®
Description: Recombinant human erythropoietin falls under the pharmacological class of haematopoietic / anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000.
Study NCT04238312 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RESPeRATE™
Description: Fifty-five anxious pediatric dental patients received a breathing session of 10 minutes, using the RESPeRATE™ device.
Study NCT04238312 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tell, Show and Do technique
Description: Fifty-five anxious pediatric dental patients received a traditional behavior management technique (Tell-Show-Do).
Study NCT01592162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol (Astra-Zeneca), NaCl 0.9%
Description: propofol administered by a closed-loop system and saline
Study NCT01592162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol 1% (Astra-Zeneca) and remifentanil
Description: propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)
Study NCT01592162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol 1% (Astra-Zeneca) and remifentanil
Description: propofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)
Study NCT01592162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol (Astra-Zeneca) and remifentanil
Description: propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)
Study NCT01592162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol (Astra-Zeneca) and remifentanil
Description: propofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)
Study NCT01592162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol (B-Braun) and NaCl 0.9%
Description: propofol administered by a closed-loop system and saline
Study NCT01592162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol (B-Braun) and remifentanil
Description: propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)
Study NCT01592162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol (B-Braun) and remifentanil
Description: propofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)
Study NCT00061516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BETAXON (levobetaxolol HCl)
Description: levobetaxolol suspension, 0.5%
Study NCT00061516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZOPT (brinzolamide)
Description: brinzolamide suspension, 1%
Study NCT04339647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The SIMS programme
Description: The intervention targets 5-6-year-old preschool children and their parents. Apart from the usual care, 5-6-year-old children receive oral health lessons and supervised daily tooth brushing (1000ppm F) at school over a period of 6 months, as well as home tooth brushing supervision by parents for 6 months. Parents/guardians attend a meeting with a DT team at school to discuss on child's oral health status, receive OHE and free toothbrush and fluoride toothpaste (1000ppm F) for child home tooth brushing, and receive 10 oral health infographic messages from DT over a period of 5 months (with printed versions available).
Study NCT03032328 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D supplement
Description: Patients will be given a dose of vitamin D for at least 2 months
Study NCT03334747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coartem
Description: Control Arm
Study NCT00598637 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus-eluting stent (Xience)
Description: stent is implanted due to randomization
Study NCT00327769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 250 mg intramuscular injection
Study NCT00598637 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (Endeavor Resolute)
Description: stent is implanted due to randomization
Study NCT04501107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of BioChaperone insulin lispro reconstituted with Humalog® (IMP1)
Description: Administration of IMP1 during a 12-hour euglycaemic clamp.
Study NCT04501107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of Ready-to-use BioChaperone insulin lispro (IMP2)
Description: Administration of IMP2 during a 12-hour euglycaemic clamp.
Study NCT04501107 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of US-approved Humalog® (IMP3)
Description: Administration of IMP3 during a 12-hour euglycaemic clamp.
Study NCT04501107 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of EU-approved Humalog® (IMP4)
Description: Administration of IMP4 during a 12-hour euglycaemic clamp.
Study NCT00788047 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dextromethorphan
Description: Dextromethorphan HCl 30 syrup single dose
Study NCT00788047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon + Dextromethorphan
Description: Dimebon 20 mg tablets given three times daily for 14 days plus Dextromethorphan HCl 30 syrup single dose administered on Day 12
Study NCT03341754 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: D/ChAd63-CA
Description: Priming Component (DNA) = NMRC-M3V-D-PfCA (D-CA) Vaccine Boosting Component = ChAd63-PfCA
Study NCT03341754 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: D/ChAd63-CAT
Description: Priming Component (DNA) = NMRC-M3V-D-PfCAT (D-CAT) Boosting Component = ChAd63-PfCAT
Study NCT03341754 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infectivity Control (IC) Group
Description: Subjects will be exposed to bites of 5 Anopheles stephensi mosquitoes carrying infectious Pf sporozoites within a controlled clinical environment.
Study NCT01961804 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Reversion
Description: Administration of prothrombin complex concentrates: KANOKAD before CT Scan
Study NCT01961804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reversion
Description: Administration of prothrombin complex concentrates: KANOKAD before CT Scan
Study NCT01072396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: double blind randomized crossover
Study NCT01072396 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: inhalation powder capsule identical to those containing tiotropium bromide inhalation powder
Study NCT00327769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: 1 mg tablet
Study NCT00327769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1 mg tablet
Study NCT00070811 — intervention group
Intervention type: PROCEDURE
Intervention: Lip revision surgery
Description: Full or partial muscle thickness lip revision surgery.
Study NCT04410289 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Airway positioning per specified protocol followed by Direct Laryngoscopy and Endotracheal Intubation
Description: Positioning of the patient's head and neck for the purpose of direct laryngoscopy and endotracheal intubation
Study NCT04410289 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Airway positioning per provider preference followed by Direct Laryngoscopy and Endotracheal Intubation
Description: Positioning of the patient's head and neck for the purpose of direct laryngoscopy and endotracheal intubation
Study NCT03458767 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eight weekly 90-minute group educational sessions
Description: Eight weekly 90-minute group educational sessions, originally developed for the MAPSS-MS intervention, adapted for remote web-based delivery.
Study NCT04409067 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: electromyography
Description: Surface electromyography (sEMG) was used as an additional non-invasive tool for assessing patients with TMD.The electromyographical (EMG) potentials of the temporalis and masseter muscles were measured with a DAB-Bluetooth Instrument (Zebris Medical GmbH, Germany) at rest and during maximum voluntary clenching (MVC).
Study NCT04287946 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: Ablation of a single-side of the greater splanchnic nerve
Study NCT00522106 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral graded activity
Description: The intervention is directed at increasing the level of activities in a time-contingent way, with the goal to integrate these activities in the daily living of the patients. The intervention is performed by physical therapists in primary care, on individual basis. Treatment period of maximal 12 weeks (with maximal 18 sessions), followed by 5 pre-set boostermoments with a maximum of 7 sessions (respectively in week 18, 25, 34, 42, and 55).
Study NCT03642860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triheptanoin
Description: Daily treatment with Triheptanoin oil for 14 days (7 days titration period in addition to 7 days full dose period with 1g/kg/day).
Study NCT03642860 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oil
Description: Daily treatment with Safflower oil for 14 days (7 days titration period in addition to 7 days full dose period with 1g/kg/day).